Project #78: Mechanisms and Delivery of FGF19 in Type 1 Diabetes
This grant funds research on how FGF19 and its analogs could prevent or delay type 1 diabetes, using advanced delivery methods to study their effects on beta cells.
Funder: Diabetes Research Connection
Due Dates: Rolling
Funding Amounts: Up to $75,000 per project; typically supports 1-year research projects.
Summary: Supports innovative research on mechanisms and delivery of FGF19 (and analogs) as a potential therapy to prevent or delay type 1 diabetes.
Key Information: Primarily for early-career scientists conducting type 1 diabetes research.
Description
This opportunity, supported by the Diabetes Research Connection (DRC), funds research projects investigating the therapeutic potential of FGF19 and its analogs in type 1 diabetes (T1D). The highlighted project explores whether increasing FGF15 (the mouse analog of human FGF19) in beta cells can prevent or delay T1D onset, using nanolipid particle technology for targeted delivery in mouse models. The goal is to lay groundwork for future human therapies targeting FGF19 in T1D. DRC focuses on supporting novel, peer-reviewed, early-stage research that advances understanding, prevention, or treatment of T1D.
